28 July 2020 : Original article
Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial
Barbara Suwelack1ABDE*, Suphamai Bunnapradist2BDE, Ulf Meier-Kriesche3ACDE, Daniel R. Stevens3ACDE, Claudio Procaccianti4ACDE, Roberto Morganti4ACDE, Klemens Budde5ACDEDOI: 10.12659/AOT.923278
Ann Transplant 2020; 25:e923278

Figure 6 Clinical outcomes overall and by metabolizer phenotype. The analysis population consisted of patients who had a calculable day 30 C/D ratio based on central or local laboratory data. For all patients and within metabolizer subgroups, there were no statistically significant differences between treatments for any event. BKV, BK viremia; BKVN – BK virus nephropathy; BPAR – biopsy-proven acute rejection; CMV – cytomegalovirus; DGF – delayed graft function.